KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Current Assets: 2019-2024

Historic Current Assets for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $1.8 billion.

  • Royalty Pharma's Current Assets rose 3.08% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 3.08%. This contributed to the annual value of $1.8 billion for FY2024, which is 41.43% up from last year.
  • Royalty Pharma's Current Assets amounted to $1.8 billion in FY2024, which was up 41.43% from $1.3 billion recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Current Assets registered a high of $2.9 billion during FY2021, and its lowest value of $1.3 billion during FY2023.
  • Over the past 3 years, Royalty Pharma's median Current Assets value was $1.8 billion (recorded in 2024), while the average stood at $1.9 billion.
  • In the last 5 years, Royalty Pharma's Current Assets spiked by 224.12% in 2020 and then tumbled by 50.13% in 2023.
  • Over the past 5 years, Royalty Pharma's Current Assets (Yearly) stood at $2.7 billion in 2020, then climbed by 6.72% to $2.9 billion in 2021, then dropped by 11.23% to $2.6 billion in 2022, then crashed by 50.13% to $1.3 billion in 2023, then surged by 41.43% to $1.8 billion in 2024.